
China has created world-class enterprises in AI, advanced manufacturing, life sciences, and clean energy. We connect global institutional investors with these opportunities through institutional-grade due diligence, geopolitical risk isolation, and full compliance pre-clearance.

China has created world-class enterprises in AI, advanced manufacturing, life sciences, and clean energy. But global institutional investors face a critical barrier: how to deploy capital into Chinese companies while managing geopolitical and regulatory risk.
We solve this through institutional-grade project discovery, rigorous due diligence, and legal structures that isolate your capital from single-jurisdiction policy changes. Every investment is pre-cleared against international compliance standards.
We identify Chinese enterprises that have achieved world-class competitive advantages in AI, advanced manufacturing, life sciences, and clean energy. These companies are ready for international capital, but lack direct access to global institutional investors.
We structure investments through offshore holding entities governed by English or New York law, with ICSID/ICC arbitration clauses. Your capital is legally isolated from single-jurisdiction policy changes.
Every Chinese company undergoes rigorous screening: financial audits, regulatory compliance, management assessment, and market validation. Only 5-10% of sourced opportunities advance to investor presentation.
Full OFAC, GDPR, CRS/FATCA, and AMLD6 compliance pre-clearance. We eliminate regulatory surprises and ensure your investment meets all applicable international standards.
From project discovery through post-investment management, we provide institutional-grade services that eliminate geopolitical risk and regulatory uncertainty.
We maintain a proprietary network across China's high-growth sectors. Our deal sourcing team identifies enterprises with world-class competitive advantages, validated business models, and international expansion readiness. Only 5-10% of sourced opportunities advance to institutional investor presentation.
Every Chinese company undergoes rigorous institutional-grade due diligence. We assess financial health, regulatory compliance, management quality, and geopolitical risk exposure. We then structure investments through offshore holding entities to legally isolate your capital from single-jurisdiction policy changes.
Before investor introduction, we conduct full compliance pre-clearance against OFAC, EU sanctions, GDPR, CRS/FATCA, and AMLD6 standards. We prepare institutional-grade investment materials: executive summary, financial models, investor presentation, and data room access.
We leverage our network of institutional investors—sovereign wealth funds, family offices, pension funds, and PE firms—to match Chinese companies with aligned capital. We manage term negotiation, legal documentation, and transaction closing.

We focus on sectors where Chinese enterprises have achieved world-class competitive advantages and are ready for global capital deployment.
Chinese AI companies have achieved parity with US peers in algorithm development, with superior access to training data and lower computational costs. Global expansion opportunity: $50B+ addressable market in enterprise AI, autonomous systems, and industrial automation.
Investment Thesis: Chinese AI teams + global capital = competitive advantage in emerging markets
China leads in decentralized physical infrastructure networks (DePIN) and blockchain infrastructure. Chinese teams have built the most efficient mining pools, Layer 2 solutions, and cross-chain bridges. Global expansion: $200B+ market for Web3 infrastructure in emerging markets.
Investment Thesis: Chinese infrastructure expertise + global regulatory clarity = market dominance
Chinese manufacturers have achieved ISO/CE certifications and are now competing on innovation, not just cost. Sectors: semiconductor equipment, EV components, industrial robotics, precision machinery. Global market: $500B+ for China-made advanced manufacturing exports.
Investment Thesis: Chinese manufacturing quality + global supply chain access = margin expansion
Chinese biotech companies are developing innovative drugs (not generics) with global patent protection. Digital health platforms serve 500M+ users. Global expansion: $100B+ market for Chinese biotech in Southeast Asia, Middle East, and emerging Europe.
Investment Thesis: Chinese R&D cost efficiency + global regulatory pathways = ROI acceleration
China manufactures 70% of global solar panels and 60% of wind turbines. Chinese clean energy companies are now building projects across Southeast Asia, Africa, and Latin America. Global market: $1T+ for clean energy deployment through 2030.
Investment Thesis: Chinese clean tech + emerging market demand = stable, long-term returns
We have successfully facilitated $500M+ in capital deployment into Chinese enterprises. These transactions demonstrate our ability to navigate complex geopolitical, regulatory, and commercial challenges for global institutional investors.
Global Institutional Capital Access
A leading Chinese AI company focused on industrial automation had developed world-class algorithms but lacked direct access to institutional capital. We structured a $50M Series B investment through an offshore holding entity with English law governance and ICSID arbitration clauses. The investor gained exposure to a $10B+ TAM with complete geopolitical risk isolation.
Chinese Technology + Regional Deployment
A Chinese clean energy company had built proprietary solar deployment technology but needed capital to scale across Southeast Asia. We identified a consortium of global PE firms, conducted full compliance pre-clearance (OFAC, GDPR, CRS/FATCA), and structured a $80M growth investment. The platform has since deployed 500MW across 5 countries.
Our compliance commitment: apply the highest applicable standard, never the lowest threshold. Compliance is not a value-added service — it is our foundational operating system.
Full anti-money laundering and know-your-customer verification per FATF 40 Recommendations and EU Sixth Anti-Money Laundering Directive.
Automated initial screening against OFAC, UN, and EU consolidated sanctions lists, followed by expert human review for all flagged entities.
Strict enforcement of EU General Data Protection Regulation and Singapore Personal Data Protection Act across all data processing activities.
Complete coverage of OECD Common Reporting Standard and US Foreign Account Tax Compliance Act reporting obligations.
All shareholder agreements governed by English or New York law, insulated from single-jurisdiction policy changes through international arbitration clauses.
Investment structures aligned with UN Principles for Responsible Investment and Task Force on Climate-related Financial Disclosures frameworks.
International Centre for Settlement of Investment Disputes and International Chamber of Commerce arbitration clauses ensuring globally enforceable investor rights.

Where multiple regulatory frameworks apply, we default to the most stringent — not the most convenient. This is our non-negotiable commitment to every institutional partner.
Whether you're exploring Chinese investment opportunities or ready to deploy capital, we have a structured engagement pathway designed for institutional investors.
Apply for access to our curated deal pipeline. Execute NDA to receive your dedicated project flow — institutional-grade opportunities screened to your investment mandate.
Request a dedicated institutional briefing to explore Chinese investment opportunities, discuss risk mitigation strategies, and learn about our deal sourcing capabilities.
All inquiries are reviewed by our institutional relations team within one business day.